Notice of Proposed Sale · 144
AtriCure, Inc.
ATRCNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- AtriCure, Inc.
- Issuer CIK
- 0001323885
- SEC file number
- 000-51470
- Phone
- 513-755-4100
- Person for whose account securities are to be sold
- Noznesky Justin J
- Relationships to issuer
- Officer
- Street
- 7555 INNOVATION WAY
- City
- MASON
- State / country code
- OH
- Postal code
- 45040
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| COMMON | 6,182 | 239,882.00 | 50,866,294 | 07/29/2026 | NASDAQ | RBC CAPITAL MARKETS LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- RBC CAPITAL MARKETS LLC
- Street
- 250 NICOLLET MALL, SUITE 1700
- City
- MINNEAPOLIS
- State / country code
- MN
- Postal code
- 55401
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON | 03/01/2023 | STOCK GRANT | ISSUER | 2,712 | N | 03/01/2023 | N/A |
| COMMON | 03/01/2024 | STOCK GRANT | ISSUER | 3,470 | N | 03/01/2024 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 07/29/2026
- Signed
- POA / JEFFREY EISCHENS
Company context
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.